250 related articles for article (PubMed ID: 28053195)
21. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D; Radhakrishnan SV; Bhardwaj N; Luetkens T
Br J Haematol; 2016 Mar; 172(5):685-98. PubMed ID: 26791002
[TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
23. Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
Mensali N; Myhre MR; Dillard P; Pollmann S; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Cancer Immunol Immunother; 2019 Aug; 68(8):1235-1243. PubMed ID: 31214732
[TBL] [Abstract][Full Text] [Related]
24. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
25. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
26. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
27. CARs in the Lead Against Multiple Myeloma.
Ormhøj M; Bedoya F; Frigault MJ; Maus MV
Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
[TBL] [Abstract][Full Text] [Related]
28. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
29. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
[TBL] [Abstract][Full Text] [Related]
30. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
31. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
32. High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells.
Kang S; Li Y; Bao Y; Li Y
Front Med; 2019 Feb; 13(1):69-82. PubMed ID: 30725257
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.
Sandri S; Bobisse S; Moxley K; Lamolinara A; De Sanctis F; Boschi F; Sbarbati A; Fracasso G; Ferrarini G; Hendriks RW; Cavallini C; Scupoli MT; Sartoris S; Iezzi M; Nishimura MI; Bronte V; Ugel S
Cancer Res; 2016 May; 76(9):2540-51. PubMed ID: 27197263
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
35. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
36. The activated conformation of integrin β
Hosen N; Matsunaga Y; Hasegawa K; Matsuno H; Nakamura Y; Makita M; Watanabe K; Yoshida M; Satoh K; Morimoto S; Fujiki F; Nakajima H; Nakata J; Nishida S; Tsuboi A; Oka Y; Manabe M; Ichihara H; Aoyama Y; Mugitani A; Nakao T; Hino M; Uchibori R; Ozawa K; Baba Y; Terakura S; Wada N; Morii E; Nishimura J; Takeda K; Oji Y; Sugiyama H; Takagi J; Kumanogoh A
Nat Med; 2017 Dec; 23(12):1436-1443. PubMed ID: 29106400
[TBL] [Abstract][Full Text] [Related]
37. Cellular Immunotherapy in B-Cell Malignancy.
Schwarzbich MA; Witzens-Harig M
Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
[TBL] [Abstract][Full Text] [Related]
38. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
39. High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar Ö; Brzezicha B; Grunert C; Kloetzel PM; Beier C; Peuker CA; Keller U; Pezzutto A; Busse A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330762
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM; van der Steen DM; Hagedoorn RS; Wouters AK; Wooldridge L; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2018 May; 26(5):1206-1214. PubMed ID: 29567312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]